Skip to main content

Translational HuPK* Platform for PK/PD of Antibody & Albumin Drug Development

Published Date

Do you need reliable pharmacokinetic (PK) data to evaluate human immunoglobulin or albumin-based therapeutic drug candidates? JAX offers HuPK*, a translational platform for therapeutic antibody PK evaluation.

The HuPK platform features several transgenic mouse models that exclusively express human FcRn. This unique platform enables you to obtain clinically relevant PK data related to drug half-life. Additionally, our human albumin model allows assessment of conjugated therapeutics. This critically important data helps optimize the design of preclinical efficacy studies and to de-risk lead selection.

Watch this webinar to learn about:

  • The biology of FcRn and its impact on immunoglobulin and albumin half-life
  • The advantages of using the HuPK platform for immunoglobulin-based therapeutic lead selection
  • Selecting and using specific variants of humanized FcRn models for drug evaluation
  • Assess PK of albumin conjugated therapeutics

*HuPK is a registered trademark in the USA and other countries